How is GSM diagnosed—do I need an examination?
Genitourinary syndrome of menopause (GSM) is often diagnosed from your history: dryness, soreness, dyspareunia, urinary urgency/frequency, and flares after friction. An examination is helpful—especially if symptoms are persistent, severe or unclear—to check for skin conditions, fissures, infection, and red flags. Tests (e.g., pH, swabs, urine) are used selectively. Treatment is usually step-wise, starting with moisturisers/lubricants, and adding local oestrogen or DHEA when needed. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
How is GSM diagnosed—do I need an examination? Diagnosis usually begins with a careful history. Your clinician will ask about vaginal dryness, friction or stinging, itching, burning, post-coital spotting (micro-tears), discomfort with sex (dyspareunia), and urinary features such as urgency, frequency or recurrent UTIs. They’ll also explore triggers (fragranced products, tight kit, cycling), medication contributors (e.g., antihistamines, anticholinergics), and life stages such as postpartum or breastfeeding that can mimic low-oestrogen patterns.
What does an examination add? A gentle external and internal assessment can confirm typical GSM changes (thin, pale epithelium, loss of rugae, higher pH), identify superficial fissures at the entrance, and—crucially—spot conditions that mimic or compound GSM. Examples include lichen sclerosus (white plaques, fragility), contact dermatitis, vestibulodynia (localised provoked pain at the vestibule), and infections such as thrush or bacterial vaginosis. If intercourse is currently too painful, examination can be deferred or modified; shared decision-making is key, and self-reported symptoms still guide initial care.
Are tests always needed? No. GSM is a clinical diagnosis; tests are used selectively to answer specific questions: a urine dip/culture if urinary symptoms suggest UTI; vaginal pH (often >5 with GSM); microscopy/cultures when discharge or odour points to thrush/BV; and dermatoscopy or biopsy only if a skin condition (e.g., lichen sclerosus) is suspected or if symptoms don’t respond as expected. Blood tests are rarely required solely for GSM.
Why an exam is worthwhile for persistent symptoms. Because GSM sits alongside other problems, an exam helps you avoid months of ineffective antifungals or steroid creams if they’re not indicated, and ensures red flags aren’t missed. It also informs a tailored plan—choosing moisturisers, the right lubricant type, considering local oestrogen/DHEA, and addressing pelvic floor overactivity or psychosexual factors if fear-avoidance has developed.
What happens after diagnosis? Management is step-wise. Start with gentle vulval care (lukewarm water; bland emollient as a soap substitute externally; avoid perfumes), schedule a vaginal moisturiser several times weekly (many prefer hyaluronic-acid formulations), and use a personal lubricant for intimacy or examinations—water-based (versatile, condom-friendly), silicone-based (longer-lasting glide for dyspareunia), or oil-based (rich feel but may degrade latex condoms and some toys). If you’d like an overview of concerns we assess and how care is delivered, see our pages on common clinical concerns and how treatment steps are sequenced.
When to escalate or refer. If symptoms persist, local vaginal oestrogen (cream, pessary/tablet, or an estradiol ring) or vaginal DHEA can restore the mucosal environment and improve lubrication, elasticity and pH. Systemic HRT helps vasomotor symptoms but often needs pairing with local therapy for GSM. Pelvic health physiotherapy can down-train overactive pelvic floor muscles and support graded return to comfortable penetration. Psychosexual therapy helps rebuild confidence, communication and pleasure-focused approaches.
Red flags to act on promptly. Post-menopausal bleeding, visible ulcers or architectural vulval changes, severe pain, fever or feeling systemically unwell, foul-smelling discharge, or visible blood in urine require timely assessment. These features point away from straightforward GSM and towards infection, dermatological disease, or other gynaecological/urological causes that need specific treatment.
Bottom line. Many people respond well to a clinical diagnosis with step-wise care; examination is recommended when symptoms are persistent, atypical or severe, or when you or your clinician want to rule out other causes. Testing is targeted—not automatic—and aims to confirm infection, assess skin disease, or evaluate urinary symptoms where relevant.
Where to read more. Practical symptom guidance is available from the NHS on vaginal dryness and on painful sex (dyspareunia). The step-wise approach to GSM is set out in the NICE Menopause Guideline (NG23). For skin conditions that can mimic GSM, see the British Association of Dermatologists on lichen sclerosus. Evidence summaries of local oestrogen are in the Cochrane Library, and peer-reviewed overviews of GSM terminology and management are indexed on PubMed.
Clinical Context
People most likely to benefit from examination include those with persistent dyspareunia, recurrent “”thrush-like”” symptoms despite antifungals, visible fissures, or urinary symptoms that don’t fit a simple UTI pattern. Examination can be adapted if penetration is painful—external inspection, pH testing, or using a smaller speculum with lubricant (compatible with any tests being taken). Those with sensitive skin, a history of dermatitis, or high-friction activities (cycling, running) often have overlapping contributors that are easier to untangle in clinic.
Seek assessment before starting new products or procedures if you have post-menopausal bleeding, ulcers/white plaques, severe or worsening pain, fever, pelvic pain, malodorous discharge, or visible blood in urine. People with a history of hormone-sensitive cancer should decide on local oestrogen or DHEA jointly with oncology and menopause teams. Non-hormonal care (scheduled moisturisers/lubricants, gentle vulval care), pelvic floor physiotherapy, and psychosexual therapy are useful adjuncts regardless of hormone use.
Evidence-Based Approaches
Guidelines endorse a clinical diagnosis supported by examination when indicated. The NICE Menopause Guideline (NG23) recommends offering information on vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen for GSM when symptoms affect quality of life, with or without systemic HRT. NHS resources provide clear advice on recognising vaginal dryness and when to seek help for dyspareunia.
Cochrane reviews find that low-dose local oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo, with broadly similar efficacy across creams, pessaries/tablets and rings, and low systemic absorption at licensed doses; see the Cochrane Library for pooled estimates and safety data. Peer-reviewed overviews indexed on PubMed summarise GSM mechanisms (thinner epithelium, raised pH, loss of lactobacilli) and compare options including vaginal DHEA, pelvic floor and psychosexual approaches.
When dermatoses are suspected, dermatology guidance (e.g., British Association of Dermatologists) supports timely diagnosis and targeted treatment, including when to consider biopsy. In practice, a step-wise plan—confirming GSM clinically, excluding mimics/infections with targeted tests, and escalating from moisturisers/lubricants to local oestrogen/DHEA—delivers the strongest balance of benefit and safety.